

Alter Ego 56.1 Statement Exhibits		
#	EXHIBIT DESCRIPTION	DEP. EXHIBIT
1.	1/27/05 Berkle (Texas) Deposition Transcript	N/A
2.	10/31/08 Berkle Deposition Transcript	N/A
3.	12/12/08 Carr-Hall Deposition Transcript	N/A
4.	6/26/02 Ciarelli Deposition Transcript	N/A
5.	7/25/07 Ciarelli Deposition Transcript	N/A
6.	5/30/07 DeCapua Deposition Transcript	N/A
7.	6/25/02 Feldman Deposition Transcript	N/A
8.	11/17/04 Feldman Deposition Transcript	N/A
9.	11/18/05 Feldman Deposition Transcript	N/A
10.	12/3/04 King Deposition Transcript	N/A
11.	5/19/09 Macey Deposition Transcript	N/A
12.	5/20/09 Macey Deposition Transcript	N/A
13.	6/27/02 Marsh Deposition Transcript	N/A
14.	5/31/07 Marsh Deposition Transcript	N/A
15.	2/26/09 McIntyre Deposition Transcript	N/A
16.	9/20/05 Paoletti Deposition Transcript	N/A
17.	11/30/05 Paoletti Deposition Transcript	N/A
18.	7/26/07 Paoletti Deposition Transcript	N/A
19.	10/11/05 Powers Deposition Transcript	N/A
20.	1/8/09 Russillo Deposition Transcript	N/A
21.	5/21/08 Shaffer Deposition Transcript	N/A
22.	8/5/08 Shaffer Deposition Transcript	N/A

23.	12/4/08 Sykora Deposition Transcript	N/A
24.	10/19/04 Tetzner Deposition Transcript	N/A
25.	10/18/05 Via Deposition Transcript	N/A
26.	10/24/01 Waterer (Texas) Deposition Transcript	N/A
27.	4/1/03 Waterer Deposition Transcript	N/A
28.	11/28/05 Waterer Deposition Transcript	N/A
29.	5/9-11/07 Waterer Deposition Transcript	N/A
30.	7/24/07 Waterer Deposition Transcript	N/A
31.	12/12/08 Waterer Deposition Transcript	N/A
32.	RLI-ORG00000016 (Jan.1998 Organization Chart)	No
33.	RLI-ORG00000023 (Jan. 2000 Organization Chart)	No
34.	BIC JURIS 0249-0259, BIC Minutes 7/17/98	No
35.	Food & Drug Administration National Drug Code Directory, <i>available at</i> http://www.accessdata.fda.gov/scripts/cder/ndc/queryndcfn.cfm	No
36.	“Roxane Laboratories Oral Solid Dosage Facility Expansion, Columbus, OH”, <i>available at</i> http://www.pharmaceutical- technology.com/projects/roxane/	No
37.	“Boehringer-Ingelheim in the United States”, <i>available at</i> http://www.pharmaceutical-technology.com/projects/roxane/	No
38.	RLI-AWP-00000001-00000069 (1996-2004 Roxane Corporate Data Sheets)	No
39.	RLI-TX 7922-7923 (Roxane Reorganization Employee Announcement)	No
40.	RLI-AWP-00104259-62 (9/15/04 Reorganization letter)	No
41.	RLI-TX 17676-17678 (Roxane Reorganization Human Resources Presentation)	No

42.	Roxane Unanimous Consents Exhibit BOEH04600117-21, BOEH04600151-54, BOEH04600159-67, BOEH04600197-09, BOEH04600226-52, BOEH04600254-63, BOEH04600267, BOEH04600292-94, BOEH04600302-06, BOEH04600326-28, BOEH04600330-39, BOEH04600363-77, BOEH04600382-85, BOEH04600392-97, BOEH04600413-15, BOEH04600430-35, BOEH04600465-77, BOEH04600504-07, BOEH04600521-29, BOEH04600533-36, BOEH04600538-44, BOEH04600609-14	No
43.	BOEH04600203 - 05 (1996 Commentary),	No
44.	BOEH02541150 - 69 (Feb. 3, 1998 Commentary 1997 Actual)	No
45.	BOEH02541103 - 22 (Commentary 1998 Year End Actual)	No
46.	BOEH02584571 - 97 (Feb. 1, 2000 Commentary 1999 Budget 1999 Actual)	No
47.	BOEH02687778 - 03 (Feb. 9, 2001 Commentary 2000 Target 2000 Actual)	No
48.	BOEH02675446 - 72 (Commentary To The Financial Statements For Year End 12/31/01)	No
49.	BOEH00147729 - 58 (2002 Year-End Financial Commentary)	No
50.	BOEH02675333 - 62 (Roxane Labs, Inc. Year End 2003 & Commentary)	No
51.	BOEH04295701 - 32 (Roxane Labs, Inc. Year End 2004 & Commentary)	No
52.	BOEH02522567 - 99 (Boehringer Ingelheim Roxane, Inc. and Roxane Laboratories, Inc. 2005 Year End Commentary)	No
53.	9/28/01 Elan Asset Purchase Agreement (BOEH01046045-1046092)	No
54.	BOEH04689322-32 (1993 Contract Manufacturing Agmt)	McIntyre Ex. 29
55.	BOEH04689307-21 (2005 BIRI/BIPI Contract Manufacturing Agmt)	McIntyre Ex. 30
56.	BOEH04689293-306 (2005 BIRI/RLI Contract Manufacturing Agmt)	McIntyre Ex. 31
57.	BOEH04689278-92 (1995 BIPI/Roxane Mexilitine License Agreement)	No

58.	D0530608 (2003 Multisource Sales & Marketing Organizational Chart)	No
59.	RLI-ORG00000080 (1996 Budget Organization Chart)	No
60.	RLI-ORG00000017 (Jan. 1998 Organizational Chart)	No
61.	RLI-AWP-00162482-484	10/31/08 Berkle Ex. 5
62.	RLI-ORG00000068 (Jan. 1998 Organigram)	No
63.	10/23/98 Reorganization Memo	10/31/08 Berkle Ex. 27
64.	RLI-AWP-00559612 (Feb. 19, 2002 Price Approval form)	No
65.	RLI-AWP-00081519 (April 1, 2002 Price Approval form)	No
66.	RLI-AWP-00083025-30 (Feb. 20, 2003 Price Approval Form)	No
67.	BOEH01140848 (Mar. 28, 2003 Price Approval Form)	No
68.	RLI-AWP-00082794-09 (June 4, 2003 Price Approval Form)	No
69.	RLI-AWP-00081645-51 (July 2, 2003 Price Approval email chain)	No
70.	Waterer 5/9/07 Deposition Exhibit 24	Waterer 024
71.	Waterer 5/9/07 Deposition Exhibit 25	Waterer 025
72.	Waterer 5/9/07 Deposition Exhibit 26	Waterer 026
73.	Waterer 5/9/07 Deposition Exhibit 27	Waterer 027
74.	Waterer 5/9/07 Deposition Exhibit 29	Waterer 029
75.	Waterer 5/9/07 Deposition Exhibit 30	Waterer 030
76.	Waterer 5/9/07 Deposition Exhibit 31	Waterer 031
77.	Waterer 5/9/07 Deposition Exhibit 34	Waterer 034
78.	Waterer 5/9/07 Deposition Exhibit 35	Waterer 035
79.	Waterer 5/9/07 Deposition Exhibit 42	Waterer 042
80.	Waterer 5/9/07 Deposition Exhibit 47	Waterer 047

81.	Feldman 11/17/04 Deposition Exhibit 93	Feldman 093
82.	Waterer 5/10/07 Deposition Exhibit 32	Waterer 032
83.	7/18/07 Roxane's Second Supp. Objections and Answers to the Commonwealth's First Set of Interrogatories (MA v. Mylan)	No
84.	RLI-ORG00000083 1(999 Roxane Sales Department Organization Chart)	No
85.	Oramorph SR Price Increase	Shaffer Dep. Ex. 10
86.	RLI-ORG00000082 (1998 Roxane Sales Department Organization Chart)	No
87.	TXEX00810 Roxane Laboratories, Inc. (Budget 1999 Organizational Chart)	1/27/05 Berkle Ex. 139
88.	Macey CV	Macey Ex. 1